Atopic dermatitis (AD) is not regarded as a predisposing condition for cutaneous T cell lymphoma. Cyclosporine (CsA) is an efficient therapy in AD, and its side effects, including lymphocytic proliferation, are rare at the low dose used in such cases. So far 3 cases of patients who developed cutaneous T cell lymphoma under CsA treatment for atopy have been described. An adult patient with a history of AD received CsA therapy because of an atypical flare-up of his eruption. He rapidly developed papular atypical lesions, then followed by the onset of a voluminous cutaneous tumor leading to the diagnosis of mycosis fungoides (MF) transformed in CD30+ large cell lymphoma with nodal and blood involvement. No improvement occurred after withdrawing of CsA, and he required a polychemotherapy and an allograft. This case illustrates the dramatic evolution of an MF under CsA given in the hypothesis of AD. It stresses the fact that skin biopsies should be taken in case of atypical AD to rule out MF and avoid such an aggressive evolution under immunosuppressive therapy.

Keywords:
Mycosis fungoides, Cyclosporine, Dermatitis, atopic, Lymphoma, cutaneous
1.
Salek MS, Finlay AY, Luscombe DK, Allen BR, Berth-Jones J, Camp RD, Graham-Brown RA, Khan GK, Marks R, Motley RJ, et al: Cyclosporine greatly improves the quality of life of adults with severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 1993;129:422.
2.
Fletcher CL, Orchard GE, Hubbard V, Whittaker SJ, Edelson RL, Russell-Jones R: CD30+ cutaneous lymphoma in association with atopic eczema. Arch Dermatol 2004;140:449.
3.
Kirby B, Owen CM, Blewitt RW, Yates VM: Cutaneous T cell lymphoma developing in a patient on cyclosporine therapy. J Am Acad Dermatol 2002;47:S165.
4.
Pielop JA, Jones D, Duvic M: Transient CD30+ nodal transformation of cutaneous T cell lymphoma associated with cyclosporine treatment. Int J Dermatol 2001;40:505.
5.
Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ: WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768–3785.
6.
Cooper DL, Braverman IM, Sarris AH, Durivage HJ, Saidman BH, Davis CA, Hait WN: Cyclosporine treatment of refractory T cell lymphomas. Cancer 1993;71:2335.
7.
Street ML, Muller SA, Pittelkow MR: Cyclosporine in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 1990;23:1084.
8.
Van Haselen CW, Toonstra J, Preesman AH, Van Der Putte SC, Bruijnzeel-Koomen CA, Van Vloten WA: Sezary syndrome in a young man with severe atopic dermatitis. Br J Dermatol 1999;140:704.
9.
Rajka G, Winkelmann RK: Atopic dermatitis and Sezary syndrome. Arch Dermatol 1984;120:83.
10.
Mehrany K, El-Azhary RA, Bouwhuis SA, Pittelkow MR: Cutaneous T cell lymphoma and atopy: is there an association? Br J Dermatol 2003;149:1013.
11.
Opelz G, Henderson R: Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342:1514.
12.
Opelz G, Schwarz V, Henderson R, Kneifel G, Ruhenstroth A: Non-Hodgkin’s lymphoma after kidney or heart transplantation: frequency of occurrence during the first posttransplant year. Transpl Int 1994;7 (suppl 1):S353.
13.
Cliff S, Pettengell R, Gharge S, Marsden RA: B cell lymphoma developing in a patient on cyclosporine for recalcitrant psoriasis. Br J Dermatol 1999;140:763.
14.
Koo JY, Kadonaga JN, Wintroub BV, Lozada-Nur FI: The development of B cell lymphoma in a patient with psoriasis treated with cyclosporine. J Am Acad Dermatol 1992;26:836.
15.
Krupp P, Monka C: Side-effect profile of cyclosporine A in patients treated for psoriasis. Br J Dermatol 1990;122(suppl 36):47.
16.
Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, Shupack J, Weinstein G: Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998;39:464.
17.
Corazza M, Zampino MR, Montanari A, Altieri E, Virgili A: Primary cutaneous CD30+ large T cell lymphoma in a patient with psoriasis treated with cyclosporine. Dermatology 2003;206:330.
18.
Mahe E, Descamps V, Grossin M, Fraitag S, Crickx B: CD30+ T cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 2003;149:170.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.